Plenary—Public Policy Outlook on Biotech Investment from China

12:45 PM - 1:40 PM, Tuesday, October 22, 2019 ・ 2nd Floor
According to Pitchbook, Chinese venture capital investment in U.S. biotechs has declined more than 60% in the first half of 2019. The increased review of the Committee on Foreign Investment in the US (CFIUS) on transactions, national security concerns, and trade negotiations have created a new landscape for cross-border business. The session will explore how biotech companies can continue to raise capital, the proposed rulemaking from CFIUS in the coming months, and a pathway for companies to remain innovative while CEOs and investors navigate these changes.

Moderator: Cameron Arterton, Vice President, Tax Policy, Biotechnology Innovation Organization
Vice President, Tax Policy
Biotechnology Innovation Organization
Greater China Managing Partner, Head of L.E.K. China and Asia Life Sciences
L.E.K. Consulting
Of Counsel
Wilson Sonsini Goodrich & Rosati
Managing Partner;Founding Partner
Kleiner Perkins Caufield & Byers China; Panacea Venture